Gregory M. Glenn, President, R&D at NOVAVAX INC (NVAX), sold 1,033 shares at $148.99 ($153K) on 2021-10-29, disclosed to the SEC on 2021-11-02.
Open-market sale of $153k NVAX by President, R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $145.41 | 39 | $6K | 3.7% |
| 2 | $146.51 | 108 | $16K | 10.3% |
| 3 | $148.08 | 138 | $20K | 13.3% |
| 4 | $148.99 | 353 | $53K | 34.3% |
| 5 | $148.99 | 353 | $53K | 34.3% |
| 6 | $149.64 | 16 |
| $2K |
| 1.6% |
| 7 | $152.16 | 26 | $4K | 2.6% |
| Total | $148.56 avg | 1,033 | $153K | 100% |
| Filing → |
| NVAX | SELL | 2021-12-09 | $1.6M | — | Filing → |
| NVAX | SELL | 2021-12-02 | $3.2M | — | Filing → |
| NVAX | SELL | 2021-11-30 | $719K | — | Filing → |